Update on the endocannabinoid-mediated regulation of gelatinase release in arterial wall physiology and atherosclerotic pathophysiology

References

• Welgus HG, Campbell EJ, Cury JD et al. Neutral metalloproteinases produced by human mononuclear phagocytes. Enzyme profile, regulation, and expression during cellular development. J. Clin. Invest. 86(5), 1496–1502 (1990).
   PubMed Web of Science ®Google Scholar
• Lenglet S, Thomas A, Chaurand P, Galan K, Mach F, Montecucco F. Molecular imaging of matrix metalloproteinases in atherosclerotic plaques. Thromb. Haemost. 107(3), 409–416 (2012).
   PubMed Web of Science ®Google Scholar
• Vuilleumier N, Bas S, Pagano S et al. Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum. 62(9), 2640–2650 (2010).
   PubMedGoogle Scholar
• Muroski ME, Roycik MD, Newcomer RG et al. Matrix metalloproteinase-9/gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis. Curr. Pharm. Biotechnol. 9(1), 34–46 (2008).
   PubMed Web of Science ®Google Scholar
• Bauvois B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim. Biophys. Acta 1825(1), 29–36 (2012).
   PubMed Web of Science ®Google Scholar
• Newby AC. Matrix metalloproteinase inhibition therapy for vascular diseases. Vascul. Pharmacol. 56(5–6), 232–244 (2012).
   PubMed Web of Science ®Google Scholar
• Ketelhuth DF, Bäck M. The role of matrix metalloproteinases in atherothrombosis. Curr. Atheroscler. Rep. 13(2), 162–169 (2011).
   PubMed Web of Science ®Google Scholar
• Montecucco F, Vuilleumier N, Pagano S et al. Anti-apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability. Eur. Heart J. 32(4), 412–421 (2011).
   Google Scholar
• De Petrocellis L, Cascio MG, Di Marzo V. The endocannabinoid system: a general view and latest additions. Br. J. Pharmacol. 141(5), 765–774 (2004).
   PubMed Web of Science ®Google Scholar
• Montecucco F, Di Marzo V, da Silva RF et al. The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. Eur. Heart J. 33(7), 846–856 (2012).
   PubMedGoogle Scholar
• Montecucco F, Matias I, Lenglet S et al. Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis. Atherosclerosis 205(2), 433–441 (2009).
   Google Scholar
• Sugamura K, Sugiyama S, Nozaki T et al. Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. Circulation 119(1), 28–36 (2009).
   PubMed Web of Science ®Google Scholar
• Bonz A, Laser M, Küllmer S et al. Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle. J. Cardiovasc. Pharmacol. 41(4), 657–664 (2003).
   PubMed Web of Science ®Google Scholar
• Bátkai S, Pacher P, Osei-Hyiaman D et al. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 110(14), 1996–2002 (2004).
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay P, Bátkai S, Rajesh M et al. Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J. Am. Coll. Cardiol. 50(6), 528–536 (2007).
   PubMed Web of Science ®Google Scholar
• Osei-Hyiaman D, DePetrillo M, Pacher P et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Invest. 115(5), 1298–1305 (2005).
   PubMed Web of Science ®Google Scholar
• Engeli S, Böhnke J, Feldpausch M et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54(10), 2838–2843 (2005).
   PubMed Web of Science ®Google Scholar
• Mallat A, Lotersztajn S. Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver. Am. J. Physiol. Gastrointest. Liver Physiol. 294(1), G9–G12 (2008).
   PubMed Web of Science ®Google Scholar
• Pacher P, Steffens S. The emerging role of the endocannabinoid system in cardiovascular disease. Semin. Immunopathol. 31(1), 63–77 (2009).
   Google Scholar
• Randall MD. Endocannabinoids and the haematological system. Br. J. Pharmacol. 152(5), 671–675 (2007).
   PubMedGoogle Scholar
• Van Sickle MD, Duncan M, Kingsley PJ et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310(5746), 329–332 (2005).
   PubMed Web of Science ®Google Scholar
• Pacher P, Gao B. Endocannabinoids and liver disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseases. Am. J. Physiol. Gastrointest. Liver Physiol. 294(4), G850–G854 (2008).
   PubMed Web of Science ®Google Scholar
• Rajesh M, Mukhopadhyay P, Bátkai S et al. CB2-receptor stimulation attenuates TNF-α-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am. J. Physiol. Heart Circ. Physiol. 293(4), H2210–H2218 (2007).
   PubMed Web of Science ®Google Scholar
• Rajesh M, Mukhopadhyay P, Haskó G, Huffman JW, Mackie K, Pacher P. CB2 cannabinoid receptor agonists attenuate TNF-α-induced human vascular smooth muscle cell proliferation and migration. Br. J. Pharmacol. 153(2), 347–357 (2008).
   PubMed Web of Science ®Google Scholar
• Quercioli A, Pataky Z, Vincenti G et al. Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. Eur. Heart J. 32(11), 1369–1378 (2011).
   PubMed Web of Science ®Google Scholar
• Járai Z, Wagner JA, Varga K et al. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl Acad. Sci. USA 96(24), 14136–14141 (1999).
   PubMed Web of Science ®Google Scholar
• O’Sullivan SE, Kendall DA, Randall MD. Heterogeneity in the mechanisms of vasorelaxation to anandamide in resistance and conduit rat mesenteric arteries. Br. J. Pharmacol. 142(3), 435–442 (2004).
   PubMed Web of Science ®Google Scholar
• Herradón E, Martín MI, López-Miranda V. Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta. Br. J. Pharmacol. 152(5), 699–708 (2007).
   Google Scholar
• Mukhopadhyay S, Chapnick BM, Howlett AC. Anandamide-induced vasorelaxation in rabbit aortic rings has two components: G protein dependent and independent. Am. J. Physiol. Heart Circ. Physiol. 282(6), H2046–H2054 (2002).
   Google Scholar
• Wagner JA, Varga K, Járai Z, Kunos G. Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension 33(1 Pt 2), 429–434 (1999).
   PubMed Web of Science ®Google Scholar
• McCollum L, Howlett AC, Mukhopadhyay S. Anandamide-mediated CB1/CB2 cannabinoid receptor–independent nitric oxide production in rabbit aortic endothelial cells. J. Pharmacol. Exp. Ther. 321(3), 930–937 (2007).
   PubMed Web of Science ®Google Scholar
• Montecucco F, Di Marzo V. At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction. Trends Pharmacol. Sci. 33(6), 331–340 (2012).
   PubMedGoogle Scholar
• Zygmunt PM, Petersson J, Andersson DA et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400(6743), 452–457 (1999).
   PubMed Web of Science ®Google Scholar
• Ralevic V, Kendall DA, Randall MD, Zygmunt PM, Movahed P, Högestätt ED. Vanilloid receptors on capsaicin-sensitive sensory nerves mediate relaxation to methanandamide in the rat isolated mesenteric arterial bed and small mesenteric arteries. Br. J. Pharmacol. 130(7), 1483–1488 (2000).
   Google Scholar
• Fernandez-Patron C, Stewart KG, Zhang Y, Koivunen E, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction. Circ. Res. 87(8), 670–676 (2000).
   PubMed Web of Science ®Google Scholar
• Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem. Pharmacol. 75(2), 346–359 (2008).
   PubMed Web of Science ®Google Scholar
• Carmeliet P. Angiogenesis in health and disease. Nat. Med. 9(6), 653–660 (2003).
   PubMed Web of Science ®Google Scholar
• Risau W. Mechanisms of angiogenesis. Nature 386(6626), 671–674 (1997).
   PubMed Web of Science ®Google Scholar
• Bussolino F, Mantovani A, Persico G. Molecular mechanisms of blood vessel formation. Trends Biochem. Sci. 22(7), 251–256 (1997).
   PubMed Web of Science ®Google Scholar
• Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler. Thromb. Vasc. Biol. 21(7), 1104–1117 (2001).
   PubMed Web of Science ®Google Scholar
• De Filippis D, Russo A, De Stefano D et al. Local administration of WIN 55,212-2 reduces chronic granuloma-associated angiogenesis in rat by inhibiting NF-κB activation. J. Mol. Med. (Berl.) 85(6), 635–645 (2007).
   Google Scholar
• Portella G, Laezza C, Laccetti P, De Petrocellis L, Di Marzo V, Bifulco M. Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J. 17(12), 1771–1773 (2003).
   PubMed Web of Science ®Google Scholar
• Casanova ML, Blázquez C, Martínez-Palacio J et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J. Clin. Invest. 111(1), 43–50 (2003).
   PubMed Web of Science ®Google Scholar
• Blazquez C, Casanova ML, Planas A et al. Inhibition of tumor angiogenesis by cannabinoids. FASEB J. 17(3), 529–531 (2003).
   PubMed Web of Science ®Google Scholar
• Pisanti S, Picardi P, Prota L et al. Genetic and pharmacologic inactivation of cannabinoid CB1 receptor inhibits angiogenesis. Blood 117(20), 5541–5550 (2011).
   PubMed Web of Science ®Google Scholar
• Blázquez C, Salazar M, Carracedo A et al. Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. Cancer Res. 68(6), 1945–1952 (2008).
   PubMed Web of Science ®Google Scholar
• Ramer R, Hinz B. Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. J. Natl Cancer Inst. 100(1), 59–69 (2008).
   PubMed Web of Science ®Google Scholar
• Ramer R, Merkord J, Rohde H, Hinz B. Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1. Biochem. Pharmacol. 79(7), 955–966 (2010).
   PubMed Web of Science ®Google Scholar
• Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol. Rev. 85(1), 1–31 (2005).
   PubMed Web of Science ®Google Scholar
• Johnson C, Galis ZS. Matrix metalloproteinase-2 and -9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization. Arterioscler. Thromb. Vasc. Biol. 24(1), 54–60 (2004).
   PubMed Web of Science ®Google Scholar
• Johnson JL, Dwivedi A, Somerville M, George SJ, Newby AC. Matrix metalloproteinase (MMP)-3 activates MMP-9 mediated vascular smooth muscle cell migration and neointima formation in mice. Arterioscler. Thromb. Vasc. Biol. 31(9), e35–e44 (2011).
   Web of Science ®Google Scholar
• Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 94(6), 2493–2503 (1994).
   PubMed Web of Science ®Google Scholar
• Jones CB, Sane DC, Herrington DM. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc. Res. 59(4), 812–823 (2003).
   PubMed Web of Science ®Google Scholar
• Blankenberg S, Rupprecht HJ, Poirier O et al.; AtheroGene Investigators. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107(12), 1579–1585 (2003).
   PubMed Web of Science ®Google Scholar
• Netherland CD, Pickle TG, Bales A, Thewke DP. Cannabinoid receptor type 2 (CB2) deficiency alters atherosclerotic lesion formation in hyperlipidemic Ldlr-null mice. Atherosclerosis 213(1), 102–108 (2010).
   Google Scholar
• Rosenstock J, Hollander P, Chevalier S, Iranmanesh A; SERENADE Study Group. SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive Type 2 diabetes. Diabetes Care 31(11), 2169–2176 (2008).
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J; RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295(7), 761–775 (2006).
   PubMed Web of Science ®Google Scholar
• Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S; RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365(9468), 1389–1397 (2005).
   PubMed Web of Science ®Google Scholar
• Topol EJ, Bousser MG, Fox KA et al.; CRESCENDO Investigators. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet 376(9740), 517–523 (2010).
   PubMed Web of Science ®Google Scholar
• Hoyer FF, Steinmetz M, Zimmer S et al. Atheroprotection via cannabinoid receptor-2 is mediated by circulating and vascular cells in vivo. J. Mol. Cell. Cardiol. 51(6), 1007–1014 (2011).
   PubMedGoogle Scholar
• Willecke F, Zeschky K, Ortiz Rodriguez A et al. Cannabinoid receptor 2 signaling does not modulate atherogenesis in mice. PLoS ONE 6(4), e19405 (2011).
   Google Scholar